Mechanisms of accelerated liver fibrosis progression during HIV infection

Journal of Clinical and Translational Hepatology

Volumn 4, Issue 4, 2016, Pages 328-335

  Debes, Jose D ^a   Bohjanen, Paul R ^a   Boonstra, Andre ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bacterial translocation; HIV; Liver fibrosis; Mitochondrial toxicity

Indexed keywords

EID: 85021879000     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2016.00034     Document Type: Review

References (97)

1. Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012;308: 370–378. doi: 10.1001/jama.2012.7844.
2. Pacheco YM, Jarrin I, Rosado I, Campins AA, Berenguer J, Iribarren JA, et al. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antiviral Res 2015;117:69–74. doi: 10.1016/j.antiviral.2015.03.002.
3. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multi-cohort collaboration. Lancet 2014;384:241–248. doi: 10.1016/S0140-6736 (14)60604-8.
4. Han SH, Kim SU, Kim CO, Jeong SJ, Park JY, Choi JY, et al. Abnormal liver stiffness assessed using transient elastography (Fibroscan®) in HIV-infected patients without HBV/HCV coinfection receiving combined antiretroviral treatment. PLoS One 2013;8:e52720. doi: 10.1371/journal.pone.0052720.
5. Redd AD, Wendel SK, Grabowski MK, Ocama P, Kiggundu V, Bbosa F, et al. Liver stiffness is associated with monocyte activation in HIV-infected Ugandans without viral hepatitis. AIDS Res Hum Retroviruses 2013;29: 1026–1030. doi: 10.1089/AID.2013.0004.
6. Konerman MA, Mehta SH, Sutcliffe CG, Vu T, Higgins Y, Torbenson MS, et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coin-fected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014;59:767–775. doi: 10.1002/hep.26741.
7. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012;32:3–13. doi: 10.1055/s-0032-1306421.
8. Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. J Hepatol 2015;62:S15–S24. doi: 10.1016/j.jhep.2015.02. 039.
9. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643–654.e649. doi: 10.1016/j.cgh.2014.04.014.
10. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425–456. doi: 10.1146/annurev-pathol-011110-130246.
11. Blackard JT, Sherman KE. HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008;15:323–330. doi: 10.1111/j.1365-2893.2008.00970.x.
12. Lin W, Weinberg EM, Chung RT. Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis 2013;207 Suppl 1:S13–S18. doi: 10.1093/infdis/jis926.
13. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 2014;28:1193–1202. doi: 10. 1097/QAD.0000000000000243.
14. Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis 2012;25:10–16. doi: 10.1097/QCO. 0b013e32834ef599.
15. Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011;377:1198–1209. doi: 10.1016/S0140-6736(10)62001-6.
16. Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther 2015;41:368–378. doi: 10.1111/apt.13052.
17. Mohammed SS, Aghdassi E, Salit IE, Avand G, Sherman M, Guindi M, et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr 2007;45:432–438. doi: 10.1097/QAI. 0b013e318074efe3.
18. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D’Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47:250–257. doi: 10.1086/589294.
19. Debes JD, Marianelli LG, Frassone N, Ballari E, Castrillon ME, Zhang L, et al. Fatty liver in hispanics with HIV. AIDS Res Hum Retroviruses 2016;32: 515–516. doi: 10.1089/AID.2016.0020.
20. Paruthi J, Gill N, Mantzoros CS. Adipokines in the HIV/HAART-associated lip-odystrophy syndrome. Metabolism 2013;62:1199–1205. doi: 10.1016/j. metabol.2013.04.014.
21. Mastroianni CM, Lichtner M, Mascia C, Zuccalà P, Vullo V. Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci 2014;15:9184– 9208. doi: 10.3390/ijms15069184.
22. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738–744. doi: 10.1053/jhep. 2001.28055.
23. Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr Opin HIV AIDS 2016;11: 234–241. doi: 10.1097/COH.0000000000000230.
24. Kiselinova M, Geretti AM, Malatinkova E, Vervisch K, Beloukas A, Messiaen P, et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. J Antimicrob Chemother 2015;70: 3311–3316. doi: 10.1093/jac/dkv250.
25. Vlahakis SR, Villasis-Keever A, Gomez TS, Bren GD, Paya CV. Human immu-nodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis 2003;188:1455–1460. doi: 10.1086/379738.
26. Nomiyama H, Hieshima K, Nakayama T, Sakaguchi T, Fujisawa R, Tanase S, et al. Human CC chemokine liver-expressed chemokine/CCL16 is a func-tional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes. Int Immunol 2001;13:1021–1029.
27. Lin W, Wu G, Li S, Weinberg EM, Kumthip K, Peng LF, et al. HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem 2011;286:2665–2674. doi: 10. 1074/jbc.M110.168286.
28. Tuyama AC, Hong F, Saiman Y, Wang C, Ozkok D, Mosoian A, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fib-rosis. Hepatology 2010;52:612–622. doi: 10.1002/hep.23679.
29. Gupta D, Rani M, Khan N, Jameel S. HIV-1 infected peripheral blood mono-nuclear cells modulate the fibrogenic activity of hepatic stellate cells through secreted TGF-b and JNK signaling. PLoS One 2014;9:e91569. doi: 10.1371/journal.pone.0091569.
30. Bruno R, Galastri S, Sacchi P, Cima S, Caligiuri A, DeFranco R, et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 2010;59:513–520. doi: 10.1136/gut. 2008.163287.
31. Rizza SA, Challagundla KB, Natesampillai S, Bren GD, Sykora J, Walczak H, et al. TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes. PLoS One 2011;6:e27171. doi: 10.1371/journal. pone.0027171.
32. Brost S, Zimmermann A, Koschny R, Sykora J, Stremmel W, Schirmacher P, et al. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. Pathol Res Pract 2014;210:83–91. doi: 10.1016/j.prp.2013.10.005.
33. Housset C, Lamas E, Bréchot C. Detection of HIV1 RNA and p24 antigen in HIV1-infected human liver. Res Virol 1990;141:153–159.
34. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009;51:212–223. doi: 10.1016/j.jhep.2009.03.008.
35. Patel P, Khan N, Rani M, Gupta D, Jameel S. The expression of HIV-1 Vpu in monocytes causes increased secretion of TGF-b that activates profibrogenic genes in hepatic stellate cells. PLoS One 2014;9:e88934. doi: 10.1371/journal.pone.0088934.
36. Page EE, Nelson M, Kelleher P. HIV and hepatitis C coinfection: pathogenesis and microbial translocation. Curr Opin HIV AIDS 2011;6:472–477. doi: 10. 1097/COH.0b013e32834bbc71.
37. Foster RG, Golden-Mason L, Rutebemberwa A, Rosen HR. Interleukin (IL)-17/ IL-22-producing T cells enriched within the liver of patients with chronic hep-hep-atitis C viral (HCV) infection. Dig Dis Sci 2012;57:381–389. doi: 10.1007/s10620-011-1997-z. atitis
38. Macek Jilkova Z, Afzal S, Marche H, Decaens T, Sturm N, Jouvin-Marche E, et al. Progression of fibrosis in patients with chronic viral hepatitis is associated with IL-17(+) neutrophils. Liver Int 2016;36:1116–1124. doi: 10. 1111/liv.13060.
39. Barrett L, Trehanpati N, Poonia S, Daigh L, Sarin SK, Masur H, et al. Hepatic compartmentalization of exhausted and regulatory cells in HIV/HCV-coinfected patients. J Viral Hepat 2015;22:281–288. doi: 10.1111/jvh.12291.
40. Vali B, Yue FY, Jones RB, Sheth PM, Kaul R, Betts MR, et al. HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PLoS One 2008;3: e3454. doi: 10.1371/journal.pone.0003454.
41. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012;10: 655–666. doi: 10.1038/nrmicro2848.
42. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365–1371. doi: 10.1038/nm1511.
43. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013;26:2–18. doi: 10.1128/CMR.00050-12.
44. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200:761–770. doi: 10.1084/jem.20041196.
45. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune acti-vation, and HIV disease. Trends Microbiol 2013;21:6–13. doi: 10.1016/j. tim.2012.09.001.
46. Corbitt N, Kimura S, Isse K, Specht S, Chedwick L, Rosborough BR, et al. Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. Am J Pathol 2013;182:180–191. doi: 10.1016/j.ajpath.2012.09.010.
47. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014;146:1513–1524. doi: 10.1053/j. gastro.2014.01.020.
48. Hufert FT, Schmitz J, Schreiber M, Schmitz H, Rácz P, von Laer DD. Human Kupffer cells infected with HIV-1 in vivo. J Acquir Immune Defic Syndr 1993; 6:772–777.
49. Balagopal A, Ray SC, De Oca RM, Sutcliffe CG, Vivekanandan P, Higgins Y, et al. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS 2009;23:2397– 2404. doi: 10.1097/QAD.0b013e3283324344.
50. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13: 1324–1332. doi: 10.1038/nm1663.
51. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991; 324:933–940. doi: 10.1056/NEJM199104043241401.
52. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001;8: 430–437.
53. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24: 99–146. doi: 10.1146/annurev.immunol.24.021605.090737.
54. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008;135:226–233. doi: 10.1053/j. gastro.2008.03.022.
55. Morse CG, Voss JG, Rakocevic G, McLaughlin M, Vinton CL, Huber C, et al. HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. J Infect Dis 2012;205:1778–1787. doi: 10.1093/infdis/jis101.
56. Maagaard A, Holberg-Petersen M, Løvgården G, Holm M, Pettersen FO, Kvale D. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment. J Infect Dis 2008; 198:1474–1481. doi: 10.1086/592713.
57. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003;21:265–304. doi: 10.1146/annurev.immunol.21.120601. 141053.
58. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adap-tations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013;58:1497–1507. doi: 10.1002/hep.26226.
59. Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev 2013;2013: 493413. doi: 10.1155/2013/493413.
60. Gallant JE, Mehta SH, Sugarman J. Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited set-tings? Clin Infect Dis 2013;57:884–887. doi: 10.1093/cid/cit382.
61. Feeney ER, Mallon PW. Impact of mitochondrial toxicity of HIV-1 antiretrovi-ral drugs on lipodystrophy and metabolic dysregulation. Curr Pharm Des 2010;16:3339–3351.
62. Galluzzi L, Pinti M, Troiano L, Prada N, Nasi M, Ferraresi R, et al. Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 2005;10:191–195.
63. Apostolova N, Blas-García A, Esplugues JV. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-g inhibition. Trends Pharmacol Sci 2011;32:715–725. doi: 10.1016/j.tips.2011.07.007.
64. Boender TS, Sigaloff KC, McMahon JH, Kiertiburanakul S, Jordan MR, Barcar-olo J, et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low-and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis 2015;61:1453–1461. doi: 10.1093/cid/civ556.
65. Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, et al. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis 2013;207 Suppl 2:S70–S77. doi: 10.1093/infdis/jit114.
66. Kooij KW, Wit FW, van Zoest RA, Schouten J, Kootstra NA, van Vugt M, et al. Liver fibrosis in HIV-infected individuals on long-term antiretroviral therapy: associated with immune activation, immunodeficiency and prior use of dida-nosine. AIDS 2016;30:1771–1780. doi: 10.1097/QAD.0000000000001119.
67. Carper MJ, Cade WT, Cam M, Zhang S, Shalev A, Yarasheski KE, et al. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2008;294:E558–567. doi: 10.1152/ajpendo.00167.2007.
68. Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, et al. The role of liver fat and insulin resistance as determinants of plasma amino-transferase elevation in nonalcoholic fatty liver disease. Hepatology 2015; 61:153–160. doi: 10.1002/hep.27395.
69. Baker J, Ayenew W, Quick H, Hullsiek KH, Tracy R, Henry K, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010;201: 285–292. doi: 10.1086/649560.
70. da Cunha J, Maselli LM, Stern AC, Spada C, Bydlowski SP. Impact of antire-troviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World J Virol 2015;4:56–77. doi: 10. 5501/wjv.v4.i2.56.
71. Justice AC, Lasky E, McGinnis KA, Skanderson M, Conigliaro J, Fultz SL, et al. Medical disease and alcohol use among veterans with human immunodefi-ciency infection: A comparison of disease measurement strategies. Med Care 2006;44:S52–S60. doi: 10.1097/01.mlr.0000228003.08925.8c.
72. Farfán Labonne BE, Gutiérrez M, Gómez-Quiroz LE, Konigsberg Fainstein M, Bucio L, Souza V, et al. Acetaldehyde-induced mitochondrial dysfunction sen-sitizes hepatocytes to oxidative damage. Cell Biol Toxicol 2009;25:599–609. doi: 10.1007/s10565-008-9115-5.
73. Bala S, Marcos M, Gattu A, Catalano D, Szabo G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS One 2014;9:e96864. doi: 10.1371/journal.pone.0096864.
74. Fuster D, Tsui JI, Cheng DM, Quinn EK, Bridden C, Nunes D, et al. Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. Alcohol Clin Exp Res 2013;37:1527– 1535. doi: 10.1111/acer.12129.
75. Bilal U, Lau B, Lazo M, McCaul ME, Hutton HE, Sulkowski MS, et al. Interaction between alcohol consumption patterns, antiretroviral therapy type, and liver fibrosis in persons living with HIV. AIDS Patient Care STDS 2016;30:200– 207. doi: 10.1089/apc.2016.0010.
76. Sherman KE, Thomas DL, Chung RT. Human immunodeficiency virus and liver disease forum 2010: conference proceedings. Hepatology 2011;54: 2245–2253. doi: 10.1002/hep.24651.
77. Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol 2014;11:362–371. doi: 10. 1038/nrgastro.2014.17.
78. Schiavini M, Angeli E, Mainini A, Uberti-Foppa C, Zerbi P, Sagnelli C, et al. Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. Hepat Mon 2011;11:525–531.
79. Leite AG, Duarte MI, Mendes-Correa MC. Fibrosis progression in paired liver biopsies from HIV/HCV-coinfected patients without prior treatment of hepatitis C. J Int Assoc Provid AIDS Care 2015;14:463–468. doi: 10.1177/2325957415587571.
80. Macias J, Japón MA, Sáez C, Palacios RB, Mira JA, García-García JA, et al. Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. J Infect Dis 2005;192:1566–1576. doi: 10.1086/491736.
81. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011;141:1220–1230, 1230. e1221–1223. doi: 10.1053/j.gastro.2011.06.063.
82. French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, et al. Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus. J Infect Dis 2013;208:679–689. doi: 10.1093/infdis/jit225.
83. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coin-fected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009;50:1056–1063. doi: 10.1002/hep.23136.
84. Presser LD, Haskett A, Waris G. Hepatitis C virus-induced furin and throm-bospondin-1 activate TGF-b1: role of TGF-b1 in HCV replication. Virology 2011;412:284–296. doi: 10.1016/j.virol.2010.12.051.
85. Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterol-ogy 2008;134:803–811. doi: 10.1053/j.gastro.2008.01.005.
86. Rockstroh JK. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals. Liver Int 2015;35 Suppl 1:51–55. doi: 10.1111/liv.12721.
87. Soriano V, Poveda E, Vispo E, Barreiro P. Hepatitis B in HIV-infected patients. Clin Liver Dis 2013;17:489–501. doi: 10.1016/j.cld.2013.05.008.
88. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007;7:402–409. doi: 10.1016/S1473-3099(07)70135-4.
89. Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997;11:597–606.
90. Crane M, Avihingsanon A, Rajasuriar R, Velayudham P, Iser D, Solomon A, et al. Lipopolysaccharide, immune activation, and liver abnormalities in HIV/hepatitis B virus (HBV)-coinfected individuals receiving HBV-active combination antiretroviral therapy. J Infect Dis 2014;210:745–751. doi: 10.1093/infdis/jiu119.
91. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009;49:1132– 1140. doi: 10.1002/hep.22751.
92. Ming D, Yu X, Guo R, Deng Y, Li J, Lin C, et al. Elevated TGF-b1/IL-31 pathway is associated with the disease severity of hepatitis B virus-related liver cir-rhosis. Viral Immunol 2015;28:209–216. doi: 10.1089/vim.2014.0142.
93. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepa-tology 2009;49:S138–S145. doi: 10.1002/hep.22883.
94. Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014;160:369–379. doi: 10.7326/M13-1829.
95. Anderson JP, Tchetgen Tchetgen EJ, Lo Re V 3rd, Tate JP, Williams PL, Seage GR 3rd, et al. Antiretroviral therapy reduces the rate of hepatic decompen-sation among HIV-and hepatitis C virus-coinfected veterans. Clin Infect Dis 2014;58:719–727. doi: 10.1093/cid/cit779.
96. Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Müllhaupt B, et al. Progression of liver fibrosis in HIV/HCV co-infection: a comparison between non-invasive assessment methods and liver biopsy. PLoS One 2015;10: e0138838. doi: 10.1371/journal.pone.0138838.
97. Sterling RK, Wegelin JA, Smith PG, Stravitz RT, Luketic VA, Fuchs M, et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol 2010;8:1070–1076. doi: 10.1016/j.cgh.2010.08.004.